Introduction {#section1-1559325817737932}
============

Several societies of cardiology and hypertension have proposed the guidelines for management, diagnosis, and treatment of hypertension.^[@bibr1-1559325817737932],[@bibr2-1559325817737932]^ These guidelines indicate no preference for specific drugs, so any first-line can be used. Some of these treatments involve the initial use of angiotensin-converting enzyme inhibitors (ACEIs), AT~1~ receptor antagonists (ARAs), calcium blockers, diuretics, or β-blockers.^[@bibr2-1559325817737932]^ In hypertension, drug combinations mentioned above are recommended if the treatment with a first-line drug does not comply with an adequate control of blood pressure (BP).^[@bibr1-1559325817737932],[@bibr2-1559325817737932]^ In this sense, the use of these combinations allows to decrease the individual dose of each drug as well as the reduction of adverse effects and improves the life quality.^[@bibr3-1559325817737932]^ These treatments induced a hypotensive effect and diminished the probability of heart failure.^[@bibr4-1559325817737932]^ However, there are combinations that are not effective, for example, the use of ARA with ACEI,^[@bibr5-1559325817737932]^ and diltiazem or verapamil with β-blockers.^[@bibr6-1559325817737932]^ The recommended combinations that have shown efficacy include the use of β-blockers with an ARA or an ACEI, but its mechanism has been insufficiently studied at molecular and physiological levels.^[@bibr2-1559325817737932]^

Although the drug action mechanisms mentioned above have been described, the antihypertensive mechanism is more complex. Indeed, the use of ACEIs is associated with an ACE reduction and ACE2 increase in expression and the production of Ang (1-7) and bradykinin, and all these mechanisms contribute to antihypertensive effect.^[@bibr7-1559325817737932][@bibr8-1559325817737932]--[@bibr9-1559325817737932]^ The effect of AT~1~ blockage is related to the reduction in ACE and the increment in ACE2 expression.^[@bibr10-1559325817737932],[@bibr11-1559325817737932]^ The β-adrenergic blockage is associated with a renin reduction, which diminishes the angiotensin I (Ang-I) levels.^[@bibr12-1559325817737932]^ All these mechanisms could conduce to an improved Ang-II or bradykinin vascular reactivity.

In this sense, when a combined treatment is used for hypertension, the interaction mechanism is even more complex. Specifically, the effect of the combined treatment with propranolol and losartan or propranolol and captopril to Ang-II and bradykinin reactivity in hypertension is unknown. For this reason, the aim of this work was to evaluate the effect of such combinations on BP and vascular reactivity to Ang-II and bradykinin in aortic ring of SHR.

Methods {#section2-1559325817737932}
=======

Animals {#section3-1559325817737932}
-------

Thirty-six male spontaneously hypertensive rats (SHRs) aged 6 to 8 months (157.83 ± 2.043 and 120.44 ± 1.76 mm Hg, systolic blood pressure \[SBP\] and diastolic blood pressure \[DBP\], respectively) and 6 Wistar Kyoto (WKY) rats (119 ± 1.33 and 80.46 ± 0.4 mm Hg, SBP and DBP, respectively) were obtained from Cinvestav-IPN, Sede Sur and maintained in the FES Cuautitlan, UNAM. All animal procedures were conducted according to the Federal Regulation for Animal Experimentation and Care (SAGARPA, NOM-062-ZOO-1999, Mexico). In all animals, the BP was evaluated noninvasively using a Medical Equipment Services (SPEM) apparatus, and the data were collected using SIEVART 1 software (from the Instituto Nacional de Cardiología "Ignacio Chavez," Mexico). The animals were randomly distributed in 7 groups: WKY vehicle (n = 6), SHR vehicle (n = 6), SHR propranolol (n = 6), SHR captopril (n = 6), SHR losartan (n = 6), SHR propranolol--captopril (n = 6), and SHR propranolol--losartan (n = 6).

Reagents {#section4-1559325817737932}
--------

Captopril, losartan, propranolol, Ang-II, and bradykinin were obtained from Sigma-Aldrich (St Louis, Missouri). Captopril, losartan, and propranolol were dissolved in physiological saline solution, and the concentration of each was adjusted to correspond with the dose administered (in milligram per kilogram) in a final volume of 0.1 mL. Ang-II and bradykinin were prepared the same day of experimentation; they were dissolved in a Krebs-Henseleit solution and kept at 4°C to avoid degradation.

Isolated Organ Bath Experiments {#section5-1559325817737932}
-------------------------------

The thoracic aorta was quickly excised and placed in a freshly prepared Krebs-Henseleit solution containing 118 mM NaCl, 4.7 mM KCl, 1.2 mM KH~2~PO~4~, 1.2 mM MgSO~4~-7H~2~O, 2.5 mM CaCl~2~-2H~2~O, 25 mM NaHCO~3~, 11.7 mM dextrose, and 0.026 mM calcium disodium EDTA bubbled with 95% O~2~/5% CO~2~. The aorta was cleaned of surrounding tissues and cut into rings of 4 to 5 mm long. The aortic rings were mounted in 10 mL isolated tissue baths filled with Krebs-Henseleit solution at 37°C (pH 7.4) and were continuously aerated with 95% O~2~/5% CO~2~. To record the development of semi-isometric force, the rings were suspended on 2 wire hooks (Nicrom wire, Quiminet, Mexico City), and one was fixed at the bottom of the chamber and the another to a force transducer (BIOPAC TSD105; BIOPAC systems Inc, Santa Barbara, California) connected to a BIOPAC MP100WSW system (from BIOPAC Systems Inc). The aortic rings were adjusted to a tension of 3 g. The response to 10^−6^ M phenylephrine was recorded every 20 minutes until the maximal reactivity was observed, which usually occurred after 1 hour. The integrity of the endothelium was evaluated by measuring the vasodilator response after the administration of 10^−5^ M acetylcholine to the aortic rings that had been pretreated with 10^−6^ M phenylephrine.

Evaluation of Antihypertensive Effect Induced by Treatments {#section6-1559325817737932}
-----------------------------------------------------------

The SHRs (n = 30) were treated with propranolol (2.5 mg/kg/d/im), losartan (1 mg/kg/d/im), captopril (1 mg/kg/d/im), propranolol--captopril (1.15 and 0.7 mg/kg/d/im, respectively), or propranolol--losartan (1.69 and 0.53 mg/kg/d/im, respectively), and the BP was measured noninvasively at the end of the treatment. The treatment was administered each day at the same time for 5 days. The individual treatments selected reduced the BP to normotensive values and were calculated through dose--effect curves using SHR, and the combination doses were calculated through isobologram method.^[@bibr13-1559325817737932]^ The results were compared with those obtained in the normotensive and hypertensive vehicle groups.

Evaluation of Vasoconstrictor Effect on Ang-II {#section7-1559325817737932}
----------------------------------------------

Concentration--response curves of Ang-II (10^−10^ to 10^−6^ M) were obtained using the rat aortic rings with intact endothelium obtained from SHR previously treated with the vehicle, propranolol, losartan, captopril, propranolol--captopril, or propranolol--losartan.

Evaluation of Vasodilator Effect on Bradykinin {#section8-1559325817737932}
----------------------------------------------

Concentration--response curves of bradykinin (10^−10^ to 10^−7^ M) were obtained using the rat aortic rings with endothelium previously precontracted with phenylephrine (10^−8^ M) from SHR treated with the vehicle, propranolol, losartan, captopril, propranolol--captopril, or propranolol--losartan.

Statistical Analysis {#section9-1559325817737932}
--------------------

Data were expressed as the mean ± standard error (SEM) of N = 12 rings from 6 rats; the differences were analyzed using 2-way analysis of variance followed by Tukey test. In all cases, *P* \<.05 was statistically significant.^[@bibr14-1559325817737932]^

Results {#section10-1559325817737932}
=======

Systolic Blood Pressure, DBP, and Heart Rate Values in Normotensive and SHR With and Without Treatment {#section11-1559325817737932}
------------------------------------------------------------------------------------------------------

[Table 1](#table1-1559325817737932){ref-type="table"} shows the SBP, DBP, and heart rate values from normotensive and hypertensive rats with and without captopril, losartan, propranolol, propranolol--captopril, propranolol--losartan treatments. By comparing with the SHR vehicle group, it is found that all treatments reduced significantly the SBP and DBP to normotensive values (*P* \< .05). With respect to heart rate, the treatments did not modify the values, but propranolol diminished it significantly (*P* \< .05).

###### 

Systolic and Diastolic Blood Pressure and Heart Rate Values Before and After Pharmacological Treatment.^a^

![](10.1177_1559325817737932-table1)

  Before Treatment                                                                         
  ------------------------- ------------------------ ------------------ ------------------ ---------------
  Wistar Kyoto (Vehicle)    119 ± 1.33^b^            80.46 ± 0.4^b^     354.87 ± 16.7      
  SHR                       Vehicle                  161.34 ± 6.78^b^   125.02 ± 6.12^b^   329.33 ± 7.93
  Captopril                 156.2 ± 6.07             119.6 ± 4.15       327.39 ± 11.86     
  Propranolol               153.56 ± 3.93            113.68 ± 4.35      359.09 ± 18.72     
  Losartan                  151 ± 3.69               113.9 ± 4.93       354.12 ± 15.06     
  Captopril + propranolol   162.6 ± 7.68             124.62 ± 7.85      355.67 ± 12.37     
                            Losartan + propranolol   162.3 ± 6.36       125.86 ± 4.87      371.83 ± 9.48
  After treatment                                                                          
  Wistar Kyoto (Vehicle)    120.42 ± 1.11^b^         81.22 ± 0.52^b^    365.52 ± 18.61     
  SHR                       Vehicle                  159.48 ± 6.2       123.16 ± 6.38      326.16 ± 8.72
  Captopril                 119.46 ± 2.34^b^         83.83 ± 1.54^b^    344.84 ± 12.06     
  Propranolol               117.58 ± 1.32^b^         89.05 ± 0.9^b^     298.89 ± 5.74^b^   
  Losartan                  120.21 ± 1.91^b^         80.91 ± 0.99^b^    314.83 ± 18.9      
  Captopril + propranolol   123.86 ± 0.95^b^         82.11 ± 1.3^b^     350.09 ± 23.27     
  Losartan + propranolol    123.97 ± 1.42^b^         85.88 ± 1.46^b^    369.24 ± 9.44      

Abbreviations: DBP, diastolic blood pressure; HR, heart rate; SBP, systolic blood pressure; SHR, spontaneously hypertensive rat.

^a^Results are shown as mean values SEM from n = 12 and 6 rats.

^b^ *P* \< .05 vs SHR.

Effects of Captopril, Propranolol, Losartan, Propranolol--Captopril, and Propranolol--Losartan on Contraction Induced by Ang-II {#section12-1559325817737932}
-------------------------------------------------------------------------------------------------------------------------------

[Figures 1](#fig1-1559325817737932){ref-type="fig"} and [2](#fig2-1559325817737932){ref-type="fig"} show the effect of several treatments on the vascular contraction induced by Ang-II, which produced a concentration-dependent contraction in aortic rings in both WKY rats and SHR, and the response was greater in SHR than in WKY. [Table 2](#table2-1559325817737932){ref-type="table"} shows the E~max~ (Maximum effect) values increased but not the EC~50~ (Effective Concentration 50) values; these results are associated with the curves of [Figures 1](#fig1-1559325817737932){ref-type="fig"} and [2](#fig2-1559325817737932){ref-type="fig"}. The propranolol and its combination with captopril increased the Ang II contractibility *vs* SHR vehicle and captopril groups. In case of losartan and propranolol--losartan treatments, the Ang-II-induced contraction diminished significantly.

![Cumulative concentration--response curve to Ang-II in aorta from rats treated with captopril (•), propranolol (◊), the captopril--propranolol interaction (♦), Wistar Kyoto (WKY) vehicle (▪), and SHR vehicle (▴). The results are shown as mean values SEM from n = 12 and 6 rats. \**P* \< .05 vs SHR. SHR indicates spontaneously hypertensive rat.](10.1177_1559325817737932-fig1){#fig1-1559325817737932}

![Cumulative concentration--response curve to Ang-II in rat aorta from rats treated with losartan (•), propranolol (◊), the losartan--propranolol interaction (♦), Wistar Kyoto (WKY) vehicle (▪), and SHR vehicle (▴). The results are shown as mean values ± EE from n = 12 and 6 rats. \**P* \< .05 vs SHR. SHR indicates spontaneously hypertensive rat.](10.1177_1559325817737932-fig2){#fig2-1559325817737932}

###### 

The E~max~ and EC~50~ Values by Ang-II and Bradykinin With Different Pharmacological Treatments.^a^

![](10.1177_1559325817737932-table2)

  Ang-II   Wistar Kyoto                     SHR                                                                                                                                  
  -------- -------------------------------- -------------------------------- ------------------------------- --------------------------------- --------------------------------- --------------------------------
  EC~50~   1.15 × 10^−8^ ± 4.34 × 10^−10^   9.04 × 10^−9^ ± 3.12 × 10^−10^   2.61 × 10^−9^ ± 1.4 × 10^−10^   3.45 × 10^−9^ ± 1.73 × 10^−10^    7.59 × 10^−9^ ± 3.05 × 10^−10^    3.55 × 10^−9^ ± 4.26 × 10^−10^
  E~max~   0.29 ± 0.026                     0.67 ± 0.058                     0.4 ± 0.03                      0.81 ± 0.08                       0.67 ± 0.04                       0.31 ± 0.03
           SHR                                                                                                                                                                   
  BK       Vehicle                          Captopril                        Propranolol                     Losartan                          Captopril + Propranolol           Losartan + Propranolol
  EC~50~   1.19 × 10^−9^ ± 1.69 × 10^−10^   1.42 × 10^−8^ ± 1.51 × 10^−9^    3.61 × 10^−9^ ± 3.5 × 10^−10^   6.45 × 10^−10^ ± 7.82 × 10^−11^   3.87 × 10^−10^ ± 5.17 × 10^−11^   7.33 × 10^−10^ ± 5.8 ×10^−11^
  E~max~   0.35 ± 0.02                      0.3 ± 0.02                       0.24 ± 0.02                     0.29 ± 0.02                       0.14 ± 0.02                       0.14 ± 0.02

Abbreviations: Ang-II, angiotensin II; BK, bradykinin; SHR, spontaneously hypertensive rat.

^a^The results are shown as mean values ± EE from n = 12 and 6 rats.

Effects of Captopril, Propranolol, Losartan, Propranolol--Captopril, and Propranolol--Losartan on the Vasodilation Induced by Bradykinin {#section13-1559325817737932}
----------------------------------------------------------------------------------------------------------------------------------------

[Figures 3](#fig3-1559325817737932){ref-type="fig"} and [4](#fig4-1559325817737932){ref-type="fig"} show the effect of several treatments on the vasodilation induced by bradykinin. From figures it can be seen that bradykinin induced a concentration-dependent vasodilator response in combined treatment, while the individual treatments did not modify such relaxation. The values of E~max~ and EC~50~ for all groups are shown in the [Table 2](#table2-1559325817737932){ref-type="table"}.

![Cumulative concentration--response curve to bradykinin in aortic rings precontracted with phenylephrine (10^−8^ M) from rats treated with captopril (•), propranolol (◊), the captopril--propranolol interaction (♦), and SHR vehicle (▴). The results are shown as mean values ± EE from n = 12 and 6 rats. \**P* \< .05 vs SHR. SHR indicates spontaneously hypertensive rat.](10.1177_1559325817737932-fig3){#fig3-1559325817737932}

![Cumulative concentration--response curve to bradykinin in aortic rings precontracted with phenylephrine (10^−8^ M) from rats treated with losartan (•), propranolol (◊), the losartan--propranolol interaction (♦), and SHR vehicle (▴). The results are shown as mean values ± EE from n = 12 and 6 rats. \**P* \< .05 vs SHR. SHR indicates spontaneously hypertensive rat.](10.1177_1559325817737932-fig4){#fig4-1559325817737932}

Discussion {#section14-1559325817737932}
==========

Results indicate that combination therapies were effective because of reduction in hypertension. The mechanism of the antihypertensive effect involved not only a reduction in reactivity to Ang-II but also an increased reactivity to bradykinin. Interestingly, the combination therapies avoid the bradycardic effect induced by propranolol.

Hypertension is a chronic disease with high prevalence and mortality in the world; this is considered as the main risk factor for other illness such as heart disease and stroke.^[@bibr15-1559325817737932]^ Hypertension in human and experimental models is characterized by structural and functional changes.^[@bibr16-1559325817737932]^ For example, the dysfunction of renin--angiotensin system promotes an increase in the vascular reactivity to Ang-II, AT~1~ receptor expression, and ACE activity and a decrease in bradykinin activity^[@bibr17-1559325817737932]^; in smooth muscle cells, the CaMKII has a role in Ang-II-dependent small artery remodeling.^[@bibr18-1559325817737932]^ The antihypertensive therapy could reverse these changes.^[@bibr19-1559325817737932]^ In this sense, it has been seen that ACEI as captopril or a new thiomorpholine compound decreases ACE messenger RNA and reactivity of Ang-II in SHR to levels obtained in normotensive rat;^[@bibr20-1559325817737932]^ propranolol treatment reduces the renin^[@bibr21-1559325817737932]^ and ACE levels in infantile hemangioma;^[@bibr22-1559325817737932]^ losartan, an ARA, attenuates cardiac oxidative stress induced by Ang-II.^[@bibr23-1559325817737932]^ According to these evidence, our data obtained corroborated the results mentioned above, due to the fact that captopril, losartan, and propranolol reduced the BP values ([Table 1](#table1-1559325817737932){ref-type="table"}) and Ang-II induced reactivity only with the 2 first while propranolol increased it ([Figures 1](#fig1-1559325817737932){ref-type="fig"} and [2](#fig2-1559325817737932){ref-type="fig"}). This effect could be related to the results obtained by Vittorio et al, where the treatment with metoprolol and carvedilol produced an increase in BP in response to Ang-II infusion.^[@bibr24-1559325817737932]^ In relation to the combination therapy, the antihypertensive mechanisms are not sufficiently studied. In this way, through synergist mechanism, the use of interactions decreased the BP by using lower doses of captopril and propranolol,^[@bibr25-1559325817737932]^ these results were corroborated by us with this combination. However, there is little evidence about the rational mechanism that supports its use. For example, nebivolol, a third-generation β~1~ adrenergic blocker, offers an additional BP reduction when it was administered in a combination therapy or as an add-on drug to the ongoing therapy with ACEI or ARA.^[@bibr26-1559325817737932]^ There are few studies that describe the use of propranolol in combination with cilazapril or captopril, and results show that both combinations reduced SBP, DBP, and plasmatic renin activity.^[@bibr27-1559325817737932],[@bibr28-1559325817737932]^

One of the mechanisms that could explain the antihypertensive effect is through changes in the vascular reactivity. In this sense, it has been found that in mesenteric bed, the renin--angiotensin system increases the norepinephrine release in SHR, and β~2~ adrenergic receptors are involved in this effect, promoting an increase in vascular reactivity through perfusion pressure augment. According to these results, the use of propranolol and captopril inhibited the norepinephrine release and reduced the perfusion pressure, the BP, and the vascular reactivity in SHR by diminishing the Ang-II level.^[@bibr29-1559325817737932]^ However, it has been found that the addition of propranolol does not increase the antihypertensive effect of captopril in the combination, as in the interaction of captopril with a diuretic, but it prolongs the action of ACEI, suggesting a pharmacokinetic interaction.^[@bibr30-1559325817737932]^ However, and in agreement with our results, it has described that treatment with captopril and a β-blocker is not very effective and might be associated with little change in the vascular reactivity to Ang-II in SHR.^[@bibr31-1559325817737932]^ In addition, in patients with primary hypertension, the propranolol treatment might be associated with reduction in heart rate,^[@bibr32-1559325817737932]^ and captopril has shown a positive chronotropic effect by using isolated dog heart.^[@bibr33-1559325817737932]^ In our study and in a similar way, propranolol showed the bradycardic effect which was avoided by the combination with captopril ([Table 1](#table1-1559325817737932){ref-type="table"}).

The antihypertensive effect of losartan is by blocking the AT~1~ receptor, reducing the Ang-II efficacy,^[@bibr34-1559325817737932]^ suggesting that AT~1~ receptor downregulation could contribute to antihypertensive effect. In agreement with these results and by using human tubular cell line (HK-2), Ang-II was able to upregulate ACE and downregulate ACE2, which were blocked by losartan but not by an AT~2~ receptor antagonist.^[@bibr35-1559325817737932]^ With respect to interaction with β-blocker and ARA, there is evidence in which an additive effect on BP reduction was described; such effect was only observed with the third-generation β-blocker but not with the first or second one.^[@bibr36-1559325817737932]^ In this sense, it has been described in hypertensive patients that valsartan in combination with nebivolol increased the antihypertensive efficacy.^[@bibr37-1559325817737932]^ These results are in agree with our results based in that losartan--propranolol induced to lower doses an antihypertensive effect than that used as single treatment ([Figure 2](#fig2-1559325817737932){ref-type="fig"}). However, this combination did not modify the response to Ang-II induced by losartan.

In addition, it has been described that hypertension is associated with reduction in vasodilator mechanisms. For example, it has been described that acetylcholine-stimulated cyclic guanosine monophosphate levels, and vasodilator activity are diminished in the aorta of SHR which was attributed to endothelial Nitric oxide (NO) reduction.^[@bibr38-1559325817737932]^ In relation to bradykinin, Ognibene et al found that the kinin-induced vasodilation in mesenteric bed was lesser in old SHRs than in young SHRs.^[@bibr39-1559325817737932]^ This difference is attributed to endothelial dysfunction. Similar results were obtained in our study by using aorta from old SHRs and only the treatment with captopril--propranolol and losartan--propranolol increased the relaxation, indicating that endothelial function improves with combination but not with monotherapy ([Figures 3](#fig3-1559325817737932){ref-type="fig"} and [4](#fig4-1559325817737932){ref-type="fig"}). However, there is evidence that propranolol increases the kinin synthesis,^[@bibr40-1559325817737932]^ and the captopril treatment produces an increase in the bradykinin levels avoiding its biotransformation through ACE.^[@bibr41-1559325817737932]^ Additionally, ACE inhibitors could increase the B~2~ receptor signal pathway^[@bibr42-1559325817737932]^ and the release or action of NO^[@bibr43-1559325817737932]^ by facilitating the prostacyclin synthesis.^[@bibr44-1559325817737932]^ Finally, in the case of losartan, AT~1~ antagonism promoted an increase in AT~2~ signaling, which in turn increased the bradykinin activity.^[@bibr45-1559325817737932]^ It is important to mention that the bradykinin effect amplifies the knowledge about the possible antihypertensive mechanism of the combined treatments which had not been reported.

In conclusion, the results suggest that the combinations between propranolol and captopril or losartan reduce BP through the participation of ACE inhibition, AT~1~ receptor blockade, bradykinin, and B~2~ receptor stimulation, which in turn explain the minor vasoconstriction induced by Ang-II in hypertension.
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